Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005790
Status:
WITHDRAWN
Last Update Posted:
2012-06-11
First Post:
2000-06-02
Brief Title:
Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Perfusion Magnetic Resonance Imaging of Brain Tumors Correlation With Indicators of Angiogenesis
Status:
WITHDRAWN
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Unable to accrue subjects
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Perfusion magnetic resonance imaging may be an effective method of measuring the growth of blood vessels in brain tumors These measurements may help doctors better diagnose and treat brain tumors
PURPOSE Pilot study to determine the effectiveness of perfusion magnetic resonance imaging in measuring the growth of blood vessels in newly diagnosed brain tumors
PURPOSE Pilot study to determine the effectiveness of perfusion magnetic resonance imaging in measuring the growth of blood vessels in newly diagnosed brain tumors
Detailed Description:
OBJECTIVES I Correlate the findings of perfusion magnetic resonance imaging with known tissue and serum markers of angiogenesis in patients with newly diagnosed surgically resectable brain tumors
OUTLINE Patients undergo perfusion magnetic resonance imaging MRI scanning with contrast in conjunction with preoperative conventional MRI scanning with contrast Patients receive gadopentetate dimeglumine IV over 5 seconds prior to perfusion MRI Gadopentetate dimeglumine is administered at a slower rate prior to conventional MRI Patients undergo blood draw to determine urokinase type plasminogen activator levels After completion of perfusion and conventional MRI scanning brain tumor tissue samples are obtained during surgical resection to determine tumor grade and type and urokinase type plasminogen activator and basic fibroblast growth factor levels If CSF removal is required during surgery then CSF samples are collected to determine urokinase type plasminogen activator and basic fibroblast growth factor levels
PROJECTED ACCRUAL A total of 10 patients will be accrued for this study
OUTLINE Patients undergo perfusion magnetic resonance imaging MRI scanning with contrast in conjunction with preoperative conventional MRI scanning with contrast Patients receive gadopentetate dimeglumine IV over 5 seconds prior to perfusion MRI Gadopentetate dimeglumine is administered at a slower rate prior to conventional MRI Patients undergo blood draw to determine urokinase type plasminogen activator levels After completion of perfusion and conventional MRI scanning brain tumor tissue samples are obtained during surgical resection to determine tumor grade and type and urokinase type plasminogen activator and basic fibroblast growth factor levels If CSF removal is required during surgery then CSF samples are collected to determine urokinase type plasminogen activator and basic fibroblast growth factor levels
PROJECTED ACCRUAL A total of 10 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NU-95C1 | None | None | None |
| NCI-G00-1738 | None | None | None |